| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| John D Carmichael, Vivien S Boner. Medical therapy: options and uses. Reviews in endocrine & metabolic disorders. vol 9. issue 1. 2008-04-30. PMID:18163211. |
currently there are three major classes of medication available for the treatment of acromegaly: somatostatin receptor ligands, growth hormone receptor antagonists, and dopamine agonists. |
2008-04-30 |
2023-08-12 |
Not clear |
| John D Carmichael, Vivien S Boner. Medical therapy: options and uses. Reviews in endocrine & metabolic disorders. vol 9. issue 1. 2008-04-30. PMID:18163211. |
somatostatin receptor ligands are the treatment of choice for acromegaly due to their effectiveness in controlling growth hormone excess in approximately 60% of patients and their beneficial effects on tumor volume. |
2008-04-30 |
2023-08-12 |
Not clear |
| Marek Bolanowski, Ewa Bar-Andziak, Beata Kos-Kudła, Barbara Krzyzanowska-Swiniarska, Andrzej Lewiński, Elzbieta Łomna-Bogdanov, Andrzej Milewicz, Jerzy Sowiński, Wojciech Zgliczyńsk. Consensus statement of the Polish Society for Endocrinology: presurgical somatostatin analogs therapy in acromegaly. Neuro endocrinology letters. vol 29. issue 1. 2008-04-17. PMID:18283267. |
consensus statement of the polish society for endocrinology: presurgical somatostatin analogs therapy in acromegaly. |
2008-04-17 |
2023-08-12 |
Not clear |
| Marek Bolanowski, Ewa Bar-Andziak, Beata Kos-Kudła, Barbara Krzyzanowska-Swiniarska, Andrzej Lewiński, Elzbieta Łomna-Bogdanov, Andrzej Milewicz, Jerzy Sowiński, Wojciech Zgliczyńsk. Consensus statement of the Polish Society for Endocrinology: presurgical somatostatin analogs therapy in acromegaly. Neuro endocrinology letters. vol 29. issue 1. 2008-04-17. PMID:18283267. |
consensus statement of the polish society for endocrinology, regarding presurgical somatostatin analogs in acromegaly has been presented. |
2008-04-17 |
2023-08-12 |
Not clear |
| Wojciech Zgliczyński, Piotr Zdunowsk. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly]. Endokrynologia Polska. vol 58. issue 5. 2008-04-11. PMID:18058736. |
aim of the study was to assess pegvisomant efficacy in treatment patients with persistent acromegaly after transspheno-ideal surgery and unsatisfactory disease control with somatostatin analogue octreotide (octr). |
2008-04-11 |
2023-08-12 |
Not clear |
| Laura De Marinis, Antonio Bianchi, Alessandra Fusco, Vincenzo Cimino, Marilda Mormando, Laura Tilaro, Gherardo Mazziotti, Alfredo Pontecorvi, Andrea Giustin. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary. vol 10. issue 3. 2008-04-02. PMID:17484056. |
long-term effects of the combination of pegvisomant with somatostatin analogs (ssa) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to ssa. |
2008-04-02 |
2023-08-12 |
Not clear |
| Lawrence A Frohman, Vivien Boner. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary. vol 10. issue 3. 2008-04-02. PMID:17534717. |
several classes of pharmacological agents are approved for the medical therapy of acromegaly, including dopamine agonists, somatostatin analogs and a growth hormone receptor antagonist. |
2008-04-02 |
2023-08-12 |
Not clear |
| Sebastian J C M M Neggers, Maarten O van Aken, Joop A M J L Janssen, Richard A Feelders, Wouter W de Herder, Aart-Jan van der Lel. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. The Journal of clinical endocrinology and metabolism. vol 92. issue 12. 2008-02-07. PMID:17895318. |
long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. |
2008-02-07 |
2023-08-12 |
Not clear |
| Sebastian J C M M Neggers, Maarten O van Aken, Joop A M J L Janssen, Richard A Feelders, Wouter W de Herder, Aart-Jan van der Lel. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. The Journal of clinical endocrinology and metabolism. vol 92. issue 12. 2008-02-07. PMID:17895318. |
we previously reported the efficacy of a combined treatment of active acromegaly with both long-acting somatostatin analogs (ssa) and pegvisomant (peg-v). |
2008-02-07 |
2023-08-12 |
Not clear |
| Anat Ben-Shlomo, Shlomo Melme. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs : the investigational drugs journal. vol 10. issue 12. 2008-01-24. PMID:18041687. |
pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and cushing's disease. |
2008-01-24 |
2023-08-12 |
human |
| Marek Bolanowski, Ewa Bar-Andziak, Beata Kos-Kudła, Barbara Krzyzanowska-Swiniarska, Andrzej Lewiński, Elzbieta Lomna-Bogdanov, Andrzej Milewicz, Jerzy Sowiński, Wojciech Zgliczyńsk. [Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly]. Endokrynologia Polska. vol 58. issue 4. 2008-01-17. PMID:18058727. |
presurgical somatostatin analogs therapy in acromegaly]. |
2008-01-17 |
2023-08-12 |
Not clear |
| Marek Bolanowski, Ewa Bar-Andziak, Beata Kos-Kudła, Barbara Krzyzanowska-Swiniarska, Andrzej Lewiński, Elzbieta Lomna-Bogdanov, Andrzej Milewicz, Jerzy Sowiński, Wojciech Zgliczyńsk. [Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly]. Endokrynologia Polska. vol 58. issue 4. 2008-01-17. PMID:18058727. |
consensus statement of the polish society of endocrinology, regarding presurgical somatostatin analogs in acromegaly has been presented. |
2008-01-17 |
2023-08-12 |
Not clear |
| Annamaria Cola. The importance of presurgical somatostatin analogue therapy in acromegaly. Endokrynologia Polska. vol 58. issue 4. 2008-01-17. PMID:18058729. |
the importance of presurgical somatostatin analogue therapy in acromegaly. |
2008-01-17 |
2023-08-12 |
Not clear |
| Annamaria Cola. The importance of presurgical somatostatin analogue therapy in acromegaly. Endokrynologia Polska. vol 58. issue 4. 2008-01-17. PMID:18058729. |
the rationale and outcome of somatostatin analogue treatment before surgery in patients with acromegaly is briefly presented. |
2008-01-17 |
2023-08-12 |
Not clear |
| Jean Christophe Maiza, Delphine Vezzosi, Maria Matta, Florence Donadille, Florence Loubes-Lacroix, Maxime Cournot, Antoine Bennet, Philippe Caro. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clinical endocrinology. vol 67. issue 2. 2008-01-10. PMID:17524029. |
the role of somatostatin analogues (ssta) in the treatment of acromegaly. |
2008-01-10 |
2023-08-12 |
Not clear |
| Pascale Abrams, Orsalia Alexopoulou, Roger Abs, Dominique Maiter, Johan Verhels. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. European journal of endocrinology. vol 157. issue 5. 2007-12-06. PMID:17984236. |
lanreotide-autogel is a depot formulation of the somatostatin analog lanreotide used in the treatment of acromegaly. |
2007-12-06 |
2023-08-12 |
Not clear |
| A N Paisley, M E Roberts, P J Traine. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clinical endocrinology. vol 66. issue 5. 2007-09-26. PMID:17388793. |
withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. |
2007-09-26 |
2023-08-12 |
Not clear |
| A N Paisley, M E Roberts, P J Traine. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clinical endocrinology. vol 66. issue 5. 2007-09-26. PMID:17388793. |
the prevalence of gallstones (gs) is increased in acromegaly and further increased by somatostatin analogue (sa) therapy. |
2007-09-26 |
2023-08-12 |
Not clear |
| b' Vicente Climent, Francisco Mar\\xc3\\xadn, Antonio Pic\\xc3\\xb. Pharmacologic therapy in growth hormone disorders and the heart. Current medicinal chemistry. vol 14. issue 13. 2007-09-17. PMID:17584052.' |
the synthesis of somatostatin analogs has provided a new approach to acromegaly treatment. |
2007-09-17 |
2023-08-12 |
Not clear |
| Sylvia L Asa, Rebecca Digiovanni, Jing Jiang, Megan L Ward, Kimberly Loesch, Shozo Yamada, Toshiaki Sano, Katsuhiko Yoshimoto, Stuart J Frank, Shereen Ezza. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer research. vol 67. issue 15. 2007-09-11. PMID:17671221. |
it explains the lack of responsiveness to somatostatin analogue therapy of this tumor type, in contrast to the exquisite sensitivity of tumors that lack aggresomes, and has therapeutic implications for the safety of gh antagonism as a therapeutic modality in acromegaly. |
2007-09-11 |
2023-08-12 |
human |